Cargando…

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma

We report on 12 consecutive patients with advanced/metastatic Ewing's sarcoma who were treated as a separate cohort of a phase 1 trial of FANG autologous immunotherapy (1 × 10(6)–2.5 × 10(7) cells/intradermal injection each month for minimum 4 months). Safety and clinical response were monitore...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghisoli, Maurizio, Barve, Minal, Schneider, Reva, Mennel, Robert, Lenarsky, Carl, Wallraven, Gladice, Pappen, Beena O, LaNoue, John, Kumar, Padmasini, Nemunaitis, Derek, Roth, Alyssa, Nemunaitis, James, Whiting, Sam, Senzer, Neil, Fletcher, Frederick A, Nemunaitis, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4817748/ https://www.ncbi.nlm.nih.gov/pubmed/25917459 http://dx.doi.org/10.1038/mt.2015.43

Ejemplares similares

Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
por: Rao, Donald D., et al.
Publicado: (2016)

Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer
por: Barve, Minal, et al.
Publicado: (2022)

Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6
por: Barve, Vedin, et al.
Publicado: (2021)

Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease
por: Simmons, Olivia, et al.
Publicado: (2012)

Pilot Study of Recurrent Ewing's Sarcoma Management with Vigil/Temozolomide/Irinotecan and Assessment of Circulating Tumor (ct) DNA
por: Anderson, Peter, et al.
Publicado: (2023)

Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
por: Oh, Johnathan, et al.
Publicado: (2020)

Emerging technologies for the genomic analysis of cancer
por: Nemunaitis, John, et al.
Publicado: (2009)

Letter to the editor: Does Dicer Expression Affect shRNA processing?
por: Senzer, Neil, et al.
Publicado: (2009)

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: let the virus be its own demise
por: Nemunaitis, John, et al.
Publicado: (2020)

Procoagulant inhibitory properties of paclitaxel poliglumex
por: Nemunaitis, John, et al.
Publicado: (2010)

Preclinical Assessment of wt GNE Gene Plasmid for Management of Hereditary Inclusion Body Myopathy 2 (HIBM2)
por: Jay, Chris, et al.
Publicado: (2008)

Safety and in vivo Expression of a GNE-Transgene: A Novel Treatment Approach for Hereditary Inclusion Body Myopathy-2
por: Phadke, Anagha P., et al.
Publicado: (2009)

ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2022)

Author Correction: ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer
por: Rocconi, Rodney P., et al.
Publicado: (2023)

Hereditary Inclusion Body Myopathy (HIBM2)
por: Jay, Chris M., et al.
Publicado: (2009)

1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2
por: Jay, C., et al.
Publicado: (2020)

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer
por: Rocconi, Rodney P., et al.
Publicado: (2021)

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer
por: Nemunaitis, John, et al.
Publicado: (2013)

Harnessing the immune response to target tumors
por: Manning, Luisa, et al.
Publicado: (2017)

Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics
por: Vorhies, John S, et al.
Publicado: (2007)

Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
por: Alqahtani, Ali, et al.
Publicado: (2019)

Outcomes of Isolated Medial Patellofemoral Ligament Reconstruction for Recurrent Patellar Instability in Ehlers-Danlos Syndrome
por: Nemunaitis, James, et al.
Publicado: (2022)

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
por: Rao, Donald D., et al.
Publicado: (2018)

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
por: Kaufman, Howard L., et al.
Publicado: (2016)

Notch1 Activation Up-Regulates Pancreatic and Duodenal Homeobox-1
por: Liu, Shi-He, et al.
Publicado: (2013)

Ovarian Cancer Immunotherapy and Personalized Medicine
por: Morand, Susan, et al.
Publicado: (2021)

Rationale for the Use of Homologous Recombination Proficient Molecular Profile as a Biomarker for Therapeutic Targeting in Ovarian Cancer
por: Nemunaitis, John, et al.
Publicado: (2023)

BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
por: Morand, Susan, et al.
Publicado: (2020)

Systemic benefit of radiation therapy via abscopal effect
por: Craig, Daniel J., et al.
Publicado: (2022)

HER2-positive metastatic cervical cancer responsive to first and second-line treatment: A case report
por: Fortman, Dylan, et al.
Publicado: (2019)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer
por: Cohen, Roger B, et al.
Publicado: (2014)

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
por: Eager, Robert M, et al.
Publicado: (2009)

Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors
por: Gordon, Michael S., et al.
Publicado: (2021)

Adenomatous polyposis coli in cancer and therapeutic implications
por: Noe, Olivia, et al.
Publicado: (2021)

Hemophagocytosis lymphocytosis presenting as pulmonary‐renal syndrome: a case report and literature review
por: Wong, Morgan, et al.
Publicado: (2017)

Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
por: Sobol, Robert E., et al.
Publicado: (2021)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma
por: Gupta, Neeraj, et al.
Publicado: (2016)

Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
por: Sliheet, Elyssa, et al.
Publicado: (2021)

NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
por: Devanaboyina, Monika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9jgar8849347plm7treahn2cve